CompletedNCT03697187
Patient Registry to Evaluate the Real-world Safety of Ruconest®
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharming Technologies B.V.
- Principal Investigator
- Anurag Relan, MDPharming Technologies BV
- Intervention
- rhC1INH(drug)
- Enrollment
- 152 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2018 – 2021
Study locations (1)
- The US Hereditary Angioedema Association, Fairfax, Virginia, United States
Collaborators
US Hereditary Angioedema Association
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03697187 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07001280A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring
- RECRUITINGPHASE3NCT06842823A Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.